

ASX Release

SUDA RELEASES VIDEO PRESENTATION FROM SINGAPORE INVESTOR SHOWCASE

PERTH, AUSTRALIA – 5 October 2015: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces the release of a video of Mr. Stephen Carter, Managing Director and CEO, presenting at the Wholesale Investor – Asia-Pacific Emerging Company Expo 2015 in Singapore on 13 August 2015.

The video can be accessed via the company's media page on the SUDA website.



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist[®], a first-in-class oral spray of zolpidem for insomnia. ZolpiMist[®] is marketed in the USA and SUDA has rights to the product outside of the Americas and South Africa. SUDA's most advanced development-stage product, ArTiMist[™], is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist[™] was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au

For personal use only